<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898140</url>
  </required_header>
  <id_info>
    <org_study_id>1027739482649/0908/4_9</org_study_id>
    <nct_id>NCT04898140</nct_id>
  </id_info>
  <brief_title>The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents</brief_title>
  <official_title>The Evaluation of the Intensity of Cellular and Humoral Immunity to COVID-19 Causative Agent in Moscow Residents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moscow Department of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moscow Institute of Physics and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Research Center Institute of Immunology, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shemyakin-Ovchinnikov Institute of bioorganic chemistry RAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Research Center of Phthisiopulmonology and Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Moscow Department of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the research is to estimate the levels of cellular and humoral immunity to the&#xD;
      severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Moscow residents over 18&#xD;
      years old. During the study, participants will be divided into four groups: healthy&#xD;
      volunteers; individuals recovered from coronavirus disease 2019 (COVID-19) with different&#xD;
      severity; individuals vaccinated against SARS-CoV-2; individuals who have had COVID-19&#xD;
      concomitantly with comorbidities that characterized by the impact on the immune system&#xD;
      (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological&#xD;
      neoplasia). For all participants included into the study peripheral blood will be collected&#xD;
      and the titers of SARS-CoV-2 specific immunoglobulins M (IgM) and immunoglobulins G (IgG),&#xD;
      frequencies of the T cells specific to nucleocapsid (N), membrane (M), and spike (S) proteins&#xD;
      of SARS-CoV-2 in peripheral blood, as well as the fractions of virus specific T helpers and&#xD;
      cytotoxic T cells will be estimated. For smaller cohorts of the participants in all groups&#xD;
      the antibody titers and T cell response levels will be examined in dynamics. All participants&#xD;
      will be monitored for the incidence of primary or repeated COVID-19 for 1-2 years after&#xD;
      inclusion in the study.&#xD;
&#xD;
      Based on the results of the study, the relationship between the formation of humoral and&#xD;
      cellular immunity against COVID-19, the duration of these types of immunity, as well as their&#xD;
      individual contribution to protection against primary or secondary SARS-CoV-2 infection will&#xD;
      be analyzed. Additionally, data concerning patients recovered from COVID-19 and having&#xD;
      concomitant diseases will provide a valuable information that may help to understand in more&#xD;
      details the mechanisms of the development of the SARS-CoV-2 specific immune response.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IgM/IgG titer</measure>
    <time_frame>At the moment of inclusion and for 1-2 years after inclusion in the study.</time_frame>
    <description>The level of SARS-CoV-2 specific IgM/IgG antibodies in blood serum.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral blood T cells specific to different SARS-CoV-2 proteins</measure>
    <time_frame>At the moment of inclusion and for 1-2 years after inclusion in the study.</time_frame>
    <description>The number of peripheral blood T cells specific to N, M or S protein of SARS-CoV-2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subpopulations of SARS-CoV-2 specific peripheral blood T lymphocytes</measure>
    <time_frame>At the moment of inclusion and for 1-2 years after inclusion in the study.</time_frame>
    <description>The number of peripheral blood T-helpers and cytotoxic T cells specific to SARS-CoV-2 coronavirus antigens.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary or repeated COVID-19 cases</measure>
    <time_frame>1-2 years after inclusion in the study.</time_frame>
    <description>Monitoring of the SARS-CoV-2 infection cases, severity of symptoms, outcomes and recovery period among participants included into the study.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">6500</enrollment>
  <condition>Covid19</condition>
  <condition>Respiratory Viral Infection</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Individuals who were not infected and not having been demonstrated COVID-19 symptoms since December 2019.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recovered</arm_group_label>
    <description>Individuals who were recovered from COVID-19 with different severity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccinated</arm_group_label>
    <description>Individuals who were vaccinated against SARS-CoV-2 with &quot;Sputnik V&quot; vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Special group</arm_group_label>
    <description>Individuals who recovered from COVID-19 concomitant with other immune-related comorbidities (tuberculosis, chronic obstructive pulmonary disease, HIV infection, hematological neoplasia).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>SARS-CoV-2 specific IgM and IgG detection</intervention_name>
    <description>Detection of IgM and IgG antibodies specific to the SARS-CoV-2 antigens in the blood serum using enzyme-linked immunosorbent assay (ELISA).</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Recovered</arm_group_label>
    <arm_group_label>Special group</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>ELISpot: detection of the T cells specific to different SARS-CoV-2 proteins</intervention_name>
    <description>Detection of peripheral blood T lymphocytes which are activated and secrete interferon gamma (IFNgamma) upon stimulation with peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, or spike glycoprotein S proteins of SARS-CoV-2 coronavirus.</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Recovered</arm_group_label>
    <arm_group_label>Special group</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Flow cytometry: detection of the SARS-CoV-2 specific T-helpers and cytotoxic T lymphocytes</intervention_name>
    <description>Detection of peripheral blood T-helpers (CD45+CD3+CD4+)* and cytotoxic T cells (CD45+CD3+CD8+)* which are activated and secrete IFNgamma and/or interleukin-2 (IL2) upon stimulation with mixture of peptides, covering the immunodominant sequence domains of the nucleocapsid N, membrane M, and spike glycoprotein S proteins of SARS-CoV-2 coronavirus. * CD, cluster of differentiation</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_label>Recovered</arm_group_label>
    <arm_group_label>Special group</arm_group_label>
    <arm_group_label>Vaccinated</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood plasma and serum. Peripheral blood mononuclear cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Residents of Moscow city over 18 years old&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  residents of the Moscow city (registered in Moscow);&#xD;
&#xD;
          -  18 years old or above;&#xD;
&#xD;
          -  signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  citizenship of a foreign state;&#xD;
&#xD;
          -  refusal to sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizaveta V. Romanova</last_name>
    <phone>+7-(495)-915-38-87</phone>
    <email>romanovaEV4@zdrav.mos.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizaveta V. Romanova</last_name>
      <phone>+7-(495)-915-38-87</phone>
      <email>romanovaEV4@zdrav.mos.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>https://mosgorzdrav.ru/en-US/index.html</url>
    <description>Sponsor's official website (Moscow Healthcare Department)</description>
  </link>
  <link>
    <url>http://gkb-23.ru</url>
    <description>Official website of Clinical City Hospital named after I.V. Davydovsky of Moscow Department of Healthcare</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>T cell immunity</keyword>
  <keyword>virus-specific antibodies</keyword>
  <keyword>protective immunity</keyword>
  <keyword>flow cytometry</keyword>
  <keyword>ELISpot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

